| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Aberrant nocturnal cortisol and disease progression in women with breast cancer
|
Zeitzer, Jamie M.
|
|
2016
|
158 |
1 |
p. 43-50
|
artikel
|
| 2 |
A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL)
|
Neugut, Alfred I.
|
|
2016
|
158 |
1 |
p. 127-138
|
artikel
|
| 3 |
A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer
|
Hickey, Martha
|
|
2016
|
158 |
1 |
p. 79-90
|
artikel
|
| 4 |
Breast cancers from black women exhibit higher numbers of immunosuppressive macrophages with proliferative activity and of crown-like structures associated with lower survival compared to non-black Latinas and Caucasians
|
Koru-Sengul, Tulay
|
|
2016
|
158 |
1 |
p. 113-126
|
artikel
|
| 5 |
Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients
|
Hein, Alexander
|
|
2016
|
158 |
1 |
p. 59-65
|
artikel
|
| 6 |
Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study
|
Doebar, Shusma C.
|
|
2016
|
158 |
1 |
p. 179-187
|
artikel
|
| 7 |
Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung
|
McCullar, Brennan
|
|
2016
|
158 |
1 |
p. 195-202
|
artikel
|
| 8 |
HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
|
Kurozumi, Sasagu
|
|
2016
|
158 |
1 |
p. 99-111
|
artikel
|
| 9 |
Measured adolescent body mass index and adult breast cancer in a cohort of 951,480 women
|
Keinan-Boker, Lital
|
|
2016
|
158 |
1 |
p. 157-167
|
artikel
|
| 10 |
Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)
|
Matter-Walstra, K.
|
|
2016
|
158 |
1 |
p. 51-57
|
artikel
|
| 11 |
Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer
|
Arun, Banu K.
|
|
2016
|
158 |
1 |
p. 67-77
|
artikel
|
| 12 |
Plasma fluorescent oxidation products and risk of estrogen receptor-negative breast cancer in the Nurses’ Health Study and Nurses’ Health Study II
|
Hirko, Kelly A.
|
|
2016
|
158 |
1 |
p. 149-155
|
artikel
|
| 13 |
Preoperative breast magnetic resonance imaging and contralateral breast cancer occurrence among older women with ductal carcinoma in situ
|
Wang, Shi-Yi
|
|
2016
|
158 |
1 |
p. 139-148
|
artikel
|
| 14 |
Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies
|
Hida, Akira I.
|
|
2016
|
158 |
1 |
p. 1-9
|
artikel
|
| 15 |
Proliferation assessment in breast carcinomas using digital image analysis based on virtual Ki67/cytokeratin double staining
|
Røge, Rasmus
|
|
2016
|
158 |
1 |
p. 11-19
|
artikel
|
| 16 |
Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer
|
Tiwari, Shruti R.
|
|
2016
|
158 |
1 |
p. 189-193
|
artikel
|
| 17 |
Stromal cells in phyllodes tumors of the breast are enriched for EZH2 and stem cell marker expression
|
Zhang, Yanhong
|
|
2016
|
158 |
1 |
p. 21-28
|
artikel
|
| 18 |
The recurrence pattern following delayed breast reconstruction after mastectomy for breast cancer suggests a systemic effect of surgery on occult dormant micrometastases
|
Dillekås, Hanna
|
|
2016
|
158 |
1 |
p. 169-178
|
artikel
|
| 19 |
Transcriptomic profiling of curcumin-treated human breast stem cells identifies a role for stearoyl-coa desaturase in breast cancer prevention
|
Colacino, Justin A.
|
|
2016
|
158 |
1 |
p. 29-41
|
artikel
|
| 20 |
Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study
|
Smyth, L. M.
|
|
2016
|
158 |
1 |
p. 91-97
|
artikel
|
Tijdschrift beschrijving